Thyroid Cancer
Conditions
Keywords
cholesterol metabolites, dendrogenin A (DDA), 6-oxo-cholestane-3β,5α-diol (OCDO), 5,6 epoxy cholesterol, thyroid cancer
Brief summary
The study team previously shown that a cholesterol metabolite, dendrogenin A (DDA) differentiates anaplastic thyroid cancer cell lines and that its mRNA expression is diminished in human radioiodine refractory thyroid cancer samples. The team aim to quantify via mass spectrometry and immunohistochemistry DDA and other cholesterol metabolites in thyroid cancer versus healthy thyroid tissue human samples.
Detailed description
Retrospective study to analyze tissue samples of patients after thyroid surgery at Claudius Regaud Institute Toulouse, France, for thyroid cancer or thyroid aggressive lymphoma or benign thyroid pathology or other head&neck pathology necessitating total thyroidectomy despite normal thyroid. Analysis focused on cholesterol metabolites quatification by mass spectrometry in liquid and gas phase.
Interventions
OTHERMetabolites dosage
On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand. The investigators will compare the rate of deregulation between sane and malignant ones.
Sponsors
Cancer Research Center of Toulouse
Institut Claudius Regaud
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who have undergone surgery at Institut Claudius Regaud for thyroid or laryngeal cancer confirmed by histology. * Patients who have consented before surgery, for the use of participants samples for future researches.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) in thyroid tissue (healthy or malignant) | 12 months after the beginning of the study | The measurement expressed in ng / g of thyroid tissue |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Presence of enzymes involved in dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production | 12 months after the beginning of the study | intensity of signal in Liquid Chromatography-Mass Spectrometry |
| Number of enzymes involved in denrognenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production | 12 months after the beginning of the study | Quantify by immunohistochemistry |
Countries
France
Outcome results
None listed